HomeCompareBOVNF vs VIG

BOVNF vs VIG: Dividend Comparison 2026

BOVNF yields 60.82% · VIG yields 1.61%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BOVNF wins by $645.8K in total portfolio value
10 years
BOVNF
BOVNF
● Live price
60.82%
Share price
$3.29
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$678.1K
Annual income
$160,128.39
Full BOVNF calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.61%
Share price
$215.06
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.3K
Annual income
$175.21
Full VIG calculator →

Portfolio growth — BOVNF vs VIG

📍 BOVNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBOVNFVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BOVNF + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BOVNF pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BOVNF
Annual income on $10K today (after 15% tax)
$5,169.37/yr
After 10yr DRIP, annual income (after tax)
$136,109.13/yr
VIG
Annual income on $10K today (after 15% tax)
$136.50/yr
After 10yr DRIP, annual income (after tax)
$148.93/yr
At 15% tax rate, BOVNF beats the other by $135,960.20/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BOVNF + VIG for your $10,000?

BOVNF: 50%VIG: 50%
100% VIG50/50100% BOVNF
Portfolio after 10yr
$355.2K
Annual income
$80,151.79/yr
Blended yield
22.57%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BOVNF buys
0
VIG buys
0
No recent congressional trades found for BOVNF or VIG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBOVNFVIG
Forward yield60.82%1.61%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$678.1K$32.3K
Annual income after 10y$160,128.39$175.21
Total dividends collected$563.7K$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: BOVNF vs VIG ($10,000, DRIP)

YearBOVNF PortfolioBOVNF Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$16,782$6,081.62$11,301$160.59+$5.5KBOVNF
2$27,495$9,538.25$12,752$162.91+$14.7KBOVNF
3$44,024$14,604.90$14,370$165.02+$29.7KBOVNF
4$68,961$21,855.37$16,176$166.93+$52.8KBOVNF
5$105,784$31,995.46$18,188$168.67+$87.6KBOVNF
6$159,058$45,869.04$20,432$170.25+$138.6KBOVNF
7$234,649$64,457.18$22,933$171.68+$211.7KBOVNF
8$339,944$88,869.20$25,720$172.98+$314.2KBOVNF
9$484,065$120,324.94$28,827$174.15+$455.2KBOVNF
10$678,078$160,128.39$32,288$175.21+$645.8KBOVNF

BOVNF vs VIG: Complete Analysis 2026

BOVNFStock

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.

Full BOVNF Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this BOVNF vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BOVNF vs SCHDBOVNF vs JEPIBOVNF vs OBOVNF vs KOBOVNF vs MAINBOVNF vs DGROBOVNF vs NOBLBOVNF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.